0001328143-21-000094.txt : 20211124 0001328143-21-000094.hdr.sgml : 20211124 20211124161116 ACCESSION NUMBER: 0001328143-21-000094 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211124 FILED AS OF DATE: 20211124 DATE AS OF CHANGE: 20211124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MAHONEY DAVID L CENTRAL INDEX KEY: 0001224091 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36399 FILM NUMBER: 211446564 MAIL ADDRESS: STREET 1: SYMANTEC CORPORATION STREET 2: 20330 STEVENS CREEK BLVD. CITY: CUPERTINO STATE: CA ZIP: 95014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc CENTRAL INDEX KEY: 0001328143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421560076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-450-3554 MAIL ADDRESS: STREET 1: 1900 POWELL ST., SUITE 1000 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc DATE OF NAME CHANGE: 20050524 4 1 wf-form4_163778824532046.xml FORM 4 X0306 4 2021-11-24 1 0001328143 Adamas Pharmaceuticals Inc ADMS 0001224091 MAHONEY DAVID L C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 1 0 0 0 Common Stock 2021-11-24 4 U 0 5000 D 0 D Common Stock 2021-11-24 4 U 0 112781 D 0 I David L. Mahoney & Winnifred C. Ellis 1998 Family Trust Stock Option (Right to Buy) 4.8 2021-11-24 4 D 0 10000 D 2029-06-04 Common Stock 10000.0 0 D Stock Option (Right to Buy) 6.08 2021-11-24 4 D 0 40000 D 2029-09-10 Common Stock 40000.0 0 D Stock Option (Right to Buy) 2.7 2021-11-24 4 D 0 10000 D 2030-06-02 Common Stock 10000.0 0 D Stock Option (Right to Buy) 5.21 2021-11-24 4 D 0 10000 D 2022-06-02 2031-06-01 Common Stock 10000.0 0 D This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). This amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. The stock option is fully vested and exercisable. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. $3.30 plus two CVRs per share underlying the stock option. The Option shares shall vest as follows: One third of the shares shall vest on each of September 11, 2020, September 11, 2021 and September 11, 2022, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. $2.02 plus two CVRs per share underlying the stock option. $5.40 plus two CVRs per share underlying the stock option. $2.89 plus two CVRs per share underlying the stock option. /s/ Brett White, Attorney-in-fact 2021-11-24